Interim data in Phase 2 study of SNT-5505 in myelofibrosis
Filed with ASX · · 5 pages · English
In the deck
Earlier from Syntara
- Presentation: Phase 2 study of SNT-5505 in myelofibrosis
- Trading Halt
- Response to ASX Price Query
- Pause in Trading
- Appendix 4E and Annual Report to shareholders
Later from Syntara
- Equity Raising Presentation
- Placement
- Acceleration of skin scarring program
- Quarterly Activities Report
- SNT-5505 awarded US FDA Fast Track designation
Follow Syntara into a list and get an email when it puts out news.
Follow Syntara